MDxHealth Acquires Bio-Techne's ExoDx Prostate Test Platform in $15 Million Strategic Deal
核心洞察
MDxHealth has completed the acquisition of Bio-Techne's ExoDx Prostate (搜索) (EPI) test platform for $15 million, structured as $5 million in stock at closing and $2.5 million annually over four years.
The ExoDx Prostate (搜索) test is a CLIA-certified, non-invasive urine-based diagnostic that uses exosome RNA (搜索) analysis to detect clinically significant prostate cancer with greater accuracy than traditional PSA (搜索) tests.
The acquisition is expected to contribute over $20 million in revenue by 2026 and accelerate MDxHealth's revenue growth to 30%, while being accretive to adjusted EBITDA starting in Q4 2025.
MDxHealth has completed its strategic acquisition of Bio-Techne Corporation (搜索)'s Exosome Diagnostics business, including the ExoDx Prostate (搜索) (EPI) test and CLIA-certified clinical laboratory, in a $15 million transaction finalized on September 15, 2025. The deal, structured as $5 million in MDxHealth stock at closing with $2.5 million in annual payments over four years, positions the precision diagnostics company to strengthen its leadership in urology and prostate cancer diagnostics.
Addressing Critical Gaps in Prostate Cancer Detection
The ExoDx Prostate (搜索) test represents a significant advancement in non-invasive prostate cancer diagnostics, addressing key limitations of traditional screening methods. Unlike conventional PSA (搜索) tests and biopsies, which are associated with high false-positive rates and patient discomfort, the ExoDx platform leverages exosome RNA (搜索) analysis to detect clinically significant prostate cancer with enhanced accuracy.
"The ExoDx Prostate (搜索) test equips men with information to make better decisions and avoid unnecessary and potentially dangerous prostate biopsies," said Michael McGarrity, Chief Executive Officer of MDxHealth. The urine-based diagnostic offers a non-invasive alternative that aligns with MDxHealth's mission to reduce invasive procedures while improving diagnostic precision.
Kim Kelderman, President and Chief Executive Officer of Bio-Techne, emphasized the strategic fit: "MDxHealth has made several strategic moves over the past few years to position the company as a leader in urology and prostate cancer diagnostics. The addition of ExoDx Prostate (搜索) to their portfolio accelerates their leadership in this market."
Financial Impact and Market Positioning
The acquisition is projected to deliver substantial financial benefits for MDxHealth. The ExoDx business is expected to contribute over $20 million in revenue by 2026, helping accelerate the company's overall revenue growth to 30%. The deal is structured to be accretive to adjusted EBITDA starting in Q4 2025, building on MDxHealth's recent achievement of positive adjusted EBITDA of $1.4 million in Q2 2025.
The transaction's deferred payment structure, with 66% of the total consideration tied to future performance, aligns the interests of both companies while preserving MDxHealth's liquidity for research and development initiatives. This approach demonstrates financial discipline as the company maintains its 2025 revenue guidance of $108-110 million.
Capitalizing on Liquid Biopsy Market Growth
The acquisition positions MDxHealth to capture a growing share of the liquid biopsy market, valued at $10.5 billion in 2025 and projected to grow at a 20% compound annual growth rate through 2033. The global liquid biopsy market is expected to reach $22.88 billion by 2030, driven by increasing demand for non-invasive tests in early detection and personalized treatment.
MDxHealth's focus on urology, particularly prostate cancer diagnostics, creates a specialized niche where the ExoDx platform's unique value proposition can differentiate the company from larger competitors in the broader oncology liquid biopsy space. The CLIA certification of the ExoDx test strengthens MDxHealth's credibility in clinical laboratories, a critical factor for physician adoption.
Strategic Integration and Future Outlook
The ExoDx acquisition complements MDxHealth's existing portfolio of tissue-based and liquid-based tests, creating a comprehensive diagnostic suite for prostate cancer. This portfolio diversification, combined with the regulatory credibility of the CLIA-certified platform, enhances the company's competitive positioning in precision diagnostics.
Bio-Techne will retain access to the proprietary exosome-based technology for ongoing kit development in its precision diagnostics growth pillar, ensuring continued innovation in the field. For Bio-Techne, the divestiture allows the company to "strengthen its foundation as a developer of innovative, high value, high margin products, tools and reagents for the life science research and clinical diagnostics markets," according to Kelderman.
The integration of ExoDx into MDxHealth's ecosystem is expected to unlock cross-selling opportunities, particularly in urology clinics and academic medical centers, as the company continues its track record of 17 consecutive quarters of 20%+ revenue growth. This acquisition represents a calculated investment in the future of non-invasive, data-driven diagnostics, positioning MDxHealth at the forefront of the transition from reactive to proactive healthcare.